Manipulation of endothelial cells by KSHV: Implications for angiogenesis and aberrant vascular differentiation

Seminars in Cancer Biology

Volumn 26, Issue , 2014, Pages 69-77

  Ojala, Päivi M ^a,b,c   Schulz, Thomas F ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Foundation for the Finnish Cancer Institute   (Finland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Angiogenesis; Cellular differentiation; Endothelial cells; Kaposi's sarcoma; KSHV; Lymphatic vasculature; Signaling; Tumor virus

Indexed keywords

BINDING PROTEIN; CYCLOSPORIN A; DOXORUBICIN; FK506 BINDING PROTEIN 12; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL MANIPULATION; DNA DAMAGE; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION; REVIEW; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; HERPESVIRIDAE INFECTIONS; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; SARCOMA, KAPOSI; VIROLOGY; VIRUS CELL TRANSFORMATION; BINDING SITE; BLOOD VESSEL PERMEABILITY; DIMERIZATION; DOWN REGULATION; INTRACELLULAR SIGNALING; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR VASCULARIZATION; UPREGULATION; VIRUS REPLICATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; SARCOMA, KAPOSI;

EID: 84901823376     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.01.008     Document Type: Review

References (113)

1. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatol Syph 1872, 4(2):265-273.
2. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266(5192):1865-1869.
3. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332(18):1186-1191.
4. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86(4):1276-1280.
5. Mesri E.A., Cesarman E., Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010, 10(10):707-719.
6. Ye F., Lei X., Gao S.J. Mechanisms of Kaposi's sarcoma-associated herpesvirus latency and reactivation. Adv Virol 2011, 2011. http://dx.doi.org/10.1155/2011/193860.
7. Gantt S., Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011, 24(4):295-301.
8. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006, 1:273-296.
9. Huang Y.Q., Li J.J., Moscatelli D., Basilico C., Nicolaides A., Zhang W.G., et al. Expression of int-2 oncogene in Kaposi's sarcoma lesions. J Clin Invest 1993, 91(3):1191-1197.
10. Stratman A.N., Davis G.E. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal 2012, 18(1):68-80.
11. Cancian L., Hansen A., Boshoff C. Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming. Trends Cell Biol 2013, 23(9):421-432.
12. Hong Y.K., Foreman K., Shin J.W., Hirakawa S., Curry C.L., Sage D.R., et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004, 36(7):683-685.
13. Wang H.W., Trotter M.W., Lagos D., Bourboulia D., Henderson S., Makinen T., et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004, 36(7):687-693.
14. Kaaya E.E., Parravicini C., Ordonez C., Gendelman R., Berti E., Gallo R.C., et al. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10(3):295-305.
15. Sturzl M., Brandstetter H., Zietz C., Eisenburg B., Raivich G., Gearing D.P., et al. Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene 1995, 10(10):2007-2016.
16. Weich H.A., Salahuddin S.Z., Gill P., Nakamura S., Gallo R.C., Folkmann J. AIDS-associated Kaposi's sarcoma-derived cells in long-term culture express and synthesize smooth muscle alpha-actin. Am J Pathol 1991, 139(6):1251-1258.
17. Harrison A.C., Kahn L.B. Myogenic cells in Kaposi's sarcoma: an ultrastructural study. J Pathol 1978, 124(3):157-160.
18. McAllister S.C., Moses A.V. Endothelial cell- and lymphocyte-based in vitro systems for understanding KSHV biology. Curr Top Microbiol Immunol 2007, 312:211-244.
19. Ciufo D.M., Cannon J.S., Poole L.J., Wu F.Y., Murray P., Ambinder R.F., et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol 2001, 75(12):5614-5626.
20. Qian L.W., Greene W., Ye F., Gao S.J. Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J Virol 2008, 82(23):11902-11912.
21. Tomescu C., Law W.K., Kedes D.H. Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol 2003, 77(17):9669-9684.
22. Mansouri M., Douglas J., Rose P.P., Gouveia K., Thomas G., Means R.E., et al. Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells. Blood 2006, 108(6):1932-1940.
23. Mansouri M., Rose P.P., Moses A.V., Fruh K. Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol 2008, 82(19):9615-9628.
24. Grossmann C., Podgrabinska S., Skobe M., Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol 2006, 80(14):7179-7185.
25. Thurau M., Marquardt G., Gonin-Laurent N., Weinlander K., Naschberger E., Jochmann R., et al. Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death. J Virol 2009, 83(2):598-611.
26. Alkharsah K.R., Singh V.V., Bosco R., Santag S., Grundhoff A., Konrad A., et al. Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells. J Virol 2011, 85(19):10375-10388.
27. Carroll P.A., Brazeau E., Lagunoff M. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 2004, 328(1):7-18.
28. Wagner D.D., Olmsted J.B., Marder V.J. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982, 95(1):355-360.
29. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93(5):741-753.
30. Masood R., Xia G., Smith D.L., Scalia P., Still J.G., Tulpule A., et al. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood 2005, 105(3):1310-1318.
31. Scehnet J.S., Ley E.J., Krasnoperov V., Liu R., Manchanda P.K., Sjoberg E., et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009, 113(1):254-263.
32. Ye F.C., Blackbourn D.J., Mengel M., Xie J.P., Qian L.W., Greene W., et al. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007, 81(8):3980-3991.
33. Vart R.J., Nikitenko L.L., Lagos D., Trotter M.W., Cannon M., Bourboulia D., et al. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 2007, 67(9):4042-4051.
34. Brown L.F., Dezube B.J., Tognazzi K., Dvorak H.F., Yancopoulos G.D. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000, 156(6):2179-2183.
35. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407(6801):242-248.
36. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322):55-60.
37. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3(3):411-423.
38. Cheng F., Pekkonen P., Laurinavicius S., Sugiyama N., Henderson S., Gunther T., et al. KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe 2011, 10(6):577-590.
39. Naranatt P.P., Krishnan H.H., Svojanovsky S.R., Bloomer C., Mathur S., Chandran B. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 2004, 64(1):72-84.
40. Yoo J., Lee H.N., Choi I., Choi D., Chung H.K., Kim K.E., et al. Opposing regulation of PROX1 by interleukin-3 receptor and NOTCH directs differential host cell fate reprogramming by Kaposi sarcoma herpes virus. PLoS Pathog 2012, 8(6):e1002770.
41. Oliver G., Srinivasan R.S. Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell. Development 2010, 137(3):363-372.
42. Jussila L., Valtola R., Partanen T.A., Salven P., Heikkila P., Matikainen M.T., et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998, 58(8):1599-1604.
43. Weninger W., Partanen T.A., Breiteneder-Geleff S., Mayer C., Kowalski H., Mildner M., et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999, 79(2):243-251.
44. Skobe M., Brown L.F., Tognazzi K., Ganju R.K., Dezube B.J., Alitalo K., et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 1999, 113(6):1047-1053.
45. Beckstead J.H., Wood G.S., Fletcher V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol 1985, 119(2):294-300.
46. Dorfman R.F. Kaposi's sarcoma: evidence supporting its origin from the lymphatic system. Lymphology 1988, 21(1):45-52.
47. Johnson N.C., Dillard M.E., Baluk P., McDonald D.M., Harvey N.L., Frase S.L., et al. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev 2008, 22(23):3282-3291.
48. Breiteneder-Geleff S., Soleiman A., Horvat R., Amann G., Kowalski H., Kerjaschki D. Podoplanin - a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Dtsch Ges Pathol 1999, 83:270-275.
49. Hansen A., Henderson S., Lagos D., Nikitenko L., Coulter E., Roberts S., et al. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev 2010, 24(2):195-205.
50. Srinivasan R.S., Dillard M.E., Lagutin O.V., Lin F.J., Tsai S., Tsai M.J., et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev 2007, 21(19):2422-2432.
51. You L.R., Lin F.J., Lee C.T., DeMayo F.J., Tsai M.J., Tsai S.Y. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 2005, 435(7038):98-104.
52. Emuss V., Lagos D., Pizzey A., Gratrix F., Henderson S.R., Boshoff C. KSHV manipulates Notch signaling by DLL4 and JAG1 to alter cell cycle genes in lymphatic endothelia. PLoS Pathog 2009, 5(10):e1000616.
53. Cheng F., Pekkonen P., Ojala P.M. Instigation of Notch signaling in the pathogenesis of Kaposi's sarcoma-associated herpesvirus and other human tumor viruses. Future Microbiol 2012, 7(10):1191-1205.
54. Gasperini P., Espigol-Frigole G., McCormick P.J., Salvucci O., Maric D., Uldrick T.S., et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res 2012, 72(5):1157-1169.
55. Liu R., Li X., Tulpule A., Zhou Y., Scehnet J.S., Zhang S., et al. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 2010, 115(4):887-895.
56. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
57. Micalizzi D.S., Ford H.L. Epithelial-mesenchymal transition in development and cancer. Future Oncol 2009, 5(8):1129-1143.
58. Potenta S., Zeisberg E., Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008, 99(9):1375-1379.
59. Medici D., Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol 2012, 22(5-6):379-384.
60. Cornali E., Zietz C., Benelli R., Weninger W., Masiello L., Breier G., et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996, 149(6):1851-1869.
61. Samaniego F., Markham P.D., Gendelman R., Watanabe Y., Kao V., Kowalski K., et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998, 152(6):1433-1443.
62. Roy D., Sin S.H., Lucas A., Venkataramanan R., Wang L., Eason A., et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 2013, 73(7):2235-2246.
63. Wang L., Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008, 68(12):4640-4648.
64. Masood R., Cesarman E., Smith D.L., Gill P.S., Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 2002, 160(1):23-29.
65. Mutlu A.D., Cavallin L.E., Vincent L., Chiozzini C., Eroles P., Duran E.M., et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007, 11(3):245-258.
66. Dai L., Bratoeva M., Toole B.P., Qin Z., Parsons C. KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction. Int J Cancer 2012, 131(4):834-843.
67. Sivakumar R., Sharma-Walia N., Raghu H., Veettil M.V., Sadagopan S., Bottero V., et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 2008, 82(4):1759-1776.
68. Poole L.J., Yu Y., Kim P.S., Zheng Q.Z., Pevsner J., Hayward G.S. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002, 76(7):3395-3420.
69. Bala K., Bosco R., Gramolelli S., Haas D.A., Kati S., Pietrek M., et al. Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCgamma1 and activating NFAT1-dependent RCAN1 expression. PLoS Pathog 2012, 8(9):e1002927.
70. Wang L., Dittmer D.P., Tomlinson C.C., Fakhari F.D., Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006, 66(7):3658-3666.
71. Wang L., Wakisaka N., Tomlinson C.C., DeWire S.M., Krall S., Pagano J.S., et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004, 64(8):2774-2781.
72. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352(13):1317-1323.
73. Bais C., Santomasso B., Coso O., Arvanitakis L., Raaka E.G., Gutkind J.S., et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998, 391(6662):86-89.
74. Bais C., Van Geelen A., Eroles P., Mutlu A., Chiozzini C., Dias S., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003, 3(2):131-143.
75. Jham B.C., Ma T., Hu J., Chaisuparat R., Friedman E.R., Pandolfi P.P., et al. Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma. PLoS ONE 2011, 6(4):e19103.
76. Montaner S., Sodhi A., Pece S., Mesri E.A., Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 2001, 61(6):2641-2648.
77. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000, 60(17):4873-4880.
78. Boshoff C., Endo Y., Collins P.D., Takeuchi Y., Reeves J.D., Schweickart V.L., et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997, 278(5336):290-294.
79. Cherqui S., Kingdon K.M., Thorpe C., Kurian S.M., Salomon D.R. Lentiviral gene delivery of vMIP-II to transplanted endothelial cells and endothelial progenitors is proangiogenic in vivo. Mol Ther 2007, 15(7):1264-1272.
80. Stine J.T., Wood C., Hill M., Epp A., Raport C.J., Schweickart V.L., et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000, 95(4):1151-1157.
81. Dairaghi D.J., Fan R.A., McMaster B.E., Hanley M.R., Schall T.J. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem 1999, 274(31):21569-21574.
82. Qin Z., Dai L., Slomiany M.G., Toole B.P., Parsons C. Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res 2010, 70(10):3884-3889.
83. Hu J., Jham B.C., Ma T., Friedman E.R., Ferreira L., Wright J.M., et al. Angiopoietin-like 4: a novel molecular hallmark in oral Kaposi's sarcoma. Oral Oncol 2011, 47(5):371-375.
84. Ma T., Jham B.C., Hu J., Friedman E.R., Basile J.R., Molinolo A., et al. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci USA 2010, 107(32):14363-14368.
85. Benedito R., Roca C., Sorensen I., Adams S., Gossler A., Fruttiger M., et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137(6):1124-1135.
86. Hellstrom M., Phng L.K., Hofmann J.J., Wallgard E., Coultas L., Lindblom P., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445(7129):776-780.
87. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444(7122):1083-1087.
88. Lagos D., Pollara G., Henderson S., Gratrix F., Fabani M., Milne R.S., et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol 2010, 12(5):513-519.
89. Bridge G., Monteiro R., Henderson S., Emuss V., Lagos D., Georgopoulou D., et al. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 2012, 120(25):5063-5072.
90. Aguilar B., Choi I., Choi D., Chung H.K., Lee S., Yoo J., et al. Lymphatic reprogramming by Kaposi sarcoma herpes virus promotes the oncogenic activity of the virus-encoded G-protein-coupled receptor. Cancer Res 2012, 72(22):5833-5842.
91. Pantanowitz L., Dezube B.J., Hernandez-Barrantes S., Tahan S.R., Dabbous M.K. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 2006, 33(12):793-798.
92. Qian L.W., Xie J., Ye F., Gao S.J. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 2007, 81(13):7001-7010.
93. Genis L., Galvez B.G., Gonzalo P., Arroyo A.G. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev 2006, 25(1):77-86.
94. Haas D.A., Bala K., Busche G., Weidner-Glunde M., Santag S., Kati S., et al. The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells. PLoS Pathog 2013, 9(11):e1003737.
95. He M., Zhang W., Bakken T., Schutten M., Toth Z., Jung J.U., et al. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res 2012, 72(14):3582-3592.
96. Austgen K., Oakes S.A., Ganem D. Multiple defects, including premature apoptosis, prevent Kaposi's sarcoma-associated herpesvirus replication in murine cells. J Virol 2012, 86(3):1877-1882.
97. Parsons C.H., Adang L.A., Overdevest J., O'Connor C.M., Taylor J.R., Camerini D., et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest 2006, 116(7):1963-1973.
98. An F.Q., Folarin H.M., Compitello N., Roth J., Gerson S.L., McCrae K.R., et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 2006, 80(10):4833-4846.
99. Jones T., Ye F., Bedolla R., Huang Y., Meng J., Qian L., et al. Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest 2012, 122(3):1076-1081.
100. Yang T.Y., Chen S.C., Leach M.W., Manfra D., Homey B., Wiekowski M., et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000, 191(3):445-454.
101. Jensen K.K., Manfra D.J., Grisotto M.G., Martin A.P., Vassileva G., Kelley K., et al. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J Immunol 2005, 174(6):3686-3694.
102. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3(1):23-36.
103. Sugaya M., Watanabe T., Yang A., Starost M.F., Kobayashi H., Atkins A.M., et al. Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. Blood 2005, 105(6):2356-2363.
104. Ojala P.M., Tiainen M., Salven P., Veikkola T., Castanos-Velez E., Sarid R., et al. Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res 1999, 59(19):4984-4989.
105. Koopal S., Furuhjelm J.H., Jarviluoma A., Jaamaa S., Pyakurel P., Pussinen C., et al. Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog 2007, 3(9):1348-1360.
106. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008, 18(5):321-329.
107. Uldrick T.S., Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 2011, 305(2):150-162.
108. Campistol J.M., Gutierrez-Dalmau A., Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004, 77(5):760-762.
109. Krown S.E., Roy D., Lee J.Y., Dezube B.J., Reid E.G., Venkataramanan R., et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012, 59(5):447-454.
110. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270(2):815-822.
111. Koon H.B., Bubley G.J., Pantanowitz L., Masiello D., Smith B., Crosby K., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005, 23(5):982-989.
112. Ardavanis A., Doufexis D., Kountourakis P., Rigatos G. A Kaposi's sarcoma complete clinical response after sorafenib administration. Ann Oncol 2008, 19(9):1658-1659.
113. Tvorogov D., Anisimov A., Zheng W., Leppanen V.M., Tammela T., Laurinavicius S., et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18(6):630-640.